RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 123,350 shares, of BioCryst common stock. The options and RSUs were granted as of April 1, 2026, as inducements material to each employee entering into emp

CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company’s new Chief Business Officer. The inducement award consisted of non-qualifi

The US FDA approved an extended dosing interval for Eylea HD (aflibercept), allowing Regeneron Pharmaceuticals to label the 8 mg intravitreal injection for dosing intervals of up to five months in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The company said this makes Eylea HD the first injectable anti-VEGF agent with a labelled interval of up to 20 weeks for both conditions, representing a label update to a product originally cleared by the US FDA in August 202

Alphamab Oncology (HKEX: 9966) revealed that anbenitamab (KN026), a bispecific anti-HER2 antibody, met its primary endpoint in the Phase III Neo-Healer trial evaluating neoadjuvant treatment of early or locally advanced HER2-positive breast cancer, with the company describing the total pathological complete response (tpCR) result as both statistically and clinically significant versus the current standard of care. Neo-Healer (KN026-004) is a randomized, open-label, multicenter Phase III study pl

Stanford University has received a USD 3.09 million UM1 award from the National Center for Advancing Translational Sciences to develop COIN, a patient-specific cardiac organoid platform that integrates AI-driven modeling, biomaterials engineering, and multi-omics analysis for preclinical cardiac disease research. The five-investigator team — Afshin Beheshti, James Zou, Joseph C. Wu, Mark A. Skylar-Scott, and Sarah C. Heilshorn — will build a new approach methodologies platform designed to model

The Trump administration has revived tariffs on imported pharmaceuticals, applying 100% levies on drugs under the authority of a trade law that seeks to secure domestic production for national security.However, the White Houses announcement Thursdayexempted a wide array of drugs imported from countries that have already signed trade deals with the U.S., by companies that have agreed to pricing and manufacturing onshoring deals, along with all generics and biosimilars.The announcement removes a p

A recent outbreak of invasive meningococcal disease in Kent, UK, has drawn global attention. BNCC has launched a series of Neisseria meningitidis quality control products, providing professional and reliable quality control solutions for related laboratories: Product No. Product Name Specifications BNCC373718 Neisseria meningitidis type B deoxyribonucleic acid liquid internal qc 10^7~10^8copies/mL；10tube/box BNCC373836 Neisseria meningitidis type B deoxyribonucleic acid liquid internal qc 10^6~1

iStock, Tingting Ji After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M&A action from other big names, including Novartis, Amgen and AbbVie. A flurry of pharma M&A over the past week has galvanized the biopharma sector, and several big names such as Amgen, AbbVie and Bristol Myers Squibb could extend the streak, according to analysts. “We believe there is more room to run,” BMO Capital Markets wrote in a Wednesday note to clients summarizing the

FRIDAY, April 3, 2026 -- Episodic heavy drinking is prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD) and is associated with significantly higher odds of advanced liver fibrosis, according to a study published online April 2 in Clinical Gastroenterology and Hepatology . Using data from the 2017 to 2023 National Health and Nutrition Examination Survey, Yinan Su, from the University of Southern California Keck School of Medicine in Los Angeles, and colleagues examined a

FRIDAY, April 3, 2026 -- Once-daily oral zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, provides a durable response in adults with moderate-to-severe plaque psoriasis (PsO), according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver. Melinda Gooderham, M.D., from the SKiN Centre for Dermatology in Peterborough, Ontario, Canada, and colleagues led the Latitude PsO 3001 and 3002 phase 3 studies in which zasoc